Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Erasca, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for cancers driven by mutations in the RAS/MAPK signaling pathway. The company operates within the biotechnology and pharmaceutical research industry, with an emphasis on discovering, developing, and potentially commercializing novel small-molecule inhibitors for genetically defined patient populations. Erasca does not currently generate commercial product revenue, and its activities are primarily funded through equity financing and strategic collaborations.
The company’s core strategy centers on addressing unmet needs in RAS-driven cancers, which historically have been difficult to treat with targeted therapies. Erasca was founded in 2018 and built its platform by assembling a pipeline of internally developed and in-licensed drug candidates targeting key nodes in the RAS/MAPK pathway. Since its inception, the company has expanded through acquisitions and partnerships to strengthen its discovery capabilities and diversify its clinical pipeline.
Business Operations
Erasca’s operations are organized around the research and development of oncology drug candidates, with a focus on RAS/MAPK Pathway Programs as its primary business segment. The company’s pipeline includes multiple clinical and preclinical assets, such as ERAS-007 (an ERK inhibitor), ERAS-601 (a SHP2 inhibitor), and ERAS-801 (a CNS-penetrant EGFR inhibitor). Revenue generation is currently limited to collaboration-related payments, while the majority of expenditures relate to R&D, clinical trials, and general corporate operations.
The company’s operations are primarily based in the United States, with clinical trials conducted both domestically and internationally through contract research organizations. Erasca controls its intellectual property portfolio through a combination of internal discovery and licensed technologies. A notable partnership includes a strategic collaboration with Pfizer Inc. to evaluate combination therapies involving ERAS-007 and Pfizer’s encorafenib, reflecting Erasca’s approach of leveraging external assets to enhance clinical development.
Strategic Position & Investments
Erasca’s strategic direction is focused on advancing a diversified pipeline of targeted oncology therapies and exploring rational combination regimens to improve treatment outcomes in RAS-driven cancers. Growth initiatives include progressing lead assets through mid- to late-stage clinical trials, expanding biomarker-driven patient selection, and developing next-generation inhibitors to address resistance mechanisms.
The company has pursued targeted acquisitions to strengthen its discovery platform, including the acquisition of Araxes Pharma, which provided access to covalent KRAS inhibitor discovery capabilities. Erasca continues to invest in emerging oncology technologies, including structure-based drug design and precision medicine approaches, while maintaining optionality for future strategic partnerships or licensing arrangements.
Geographic Footprint
Erasca is headquartered in the United States, with its principal executive offices located in San Diego, California, a major biotechnology hub. The company’s operational footprint is primarily concentrated in North America, where its research, management, and core corporate functions are based.
Internationally, Erasca has a clinical presence in Europe and other regions through multinational clinical trials, reflecting its strategy to access diverse patient populations and accelerate development timelines. While the company does not maintain significant physical infrastructure outside the United States, its global clinical operations provide international exposure and regulatory engagement.
Leadership & Governance
Erasca is led by an executive team with experience in oncology drug development, clinical research, and biotechnology company building. The leadership emphasizes a strategy centered on scientific rigor, precision medicine, and disciplined capital allocation to advance high-impact oncology programs.
Key executives include:
- Jonathan E. Lim – President and Chief Executive Officer
- Andrew J. Orth – Chief Financial Officer
- Geoffrey Smith – Chief Business Officer
- David L. Scheinberg – Chief Medical Officer
- Kenneth H. Carling – Chief Scientific Officer
The company is governed by a board of directors with backgrounds in biopharmaceutical development, corporate governance, and healthcare investing, supporting Erasca’s long-term strategic vision and oversight.